Merck announced its plan to acquire Acceleron in September, saying it would pay $180 per share in cash.
The acquisition expands Merck’s rare disease drug portfolio, as it allows the company to take over Acceleron’s lead drug candidate, sotatercept. Merck will also gain access to Reblozyl, a drug Acceleron developed to treat anemia in certain rare blood disorders.
“This is an important and strategic opportunity for our company to continue growing our cardiovascular portfolio and pipeline that builds on our long and proud legacy in cardiovascular disease and further bolsters our business development strategy,” Rob Davis, Merck’s CEO and president, said in a statement.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
